Genetic diseases

Genetics researcher
#Gene therapy #Genespire #Genetic diseases #Paediatrics

Long-term study to inform gene therapy development

Genespire has commenced patient enrolment in an observational study, InforMMA, in children with methylmalonic acidemia (MMA) caused by mutations in the MMUT gene.  The study is designed to follow patients aged up to 16 years who live with severe MMA, with the aim of better characterising disease… Read More

#News

Genetics researcher
#Genetic diseases #Genetics / genomics #Investment #Medical Research Council

New multi-million pound UK centre to research fatal genetic diseases

The UK’s Medical Research Council has invested £50 ($67.3) million into the study of mitochondrial diseases for improved treatments.   The new MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics brings together leading experts from across disciplines to define how mutations in mitochondrial DNA (mtDNA) cause disease… Read More

#News

Genetic research
#Genetic diseases #Genomics

Genomics technology could ‘end diagnostic odysseys’   

Illumina has launched its TruPath Genome to provide researchers with a more complete picture of genomics alterations in genetic disease.  The company claims the technology fully phases more than 98% of genes, eliminating traditional library prep and generating 16 whole genomes per day in 10 minutes of hands-on time. … Read More

#News

Sickle cells
#Beam Therapeutics #Genetic diseases #Sickle cells

Beam expands liver-targeted genetic disease programme 

Biotechnology company Beam Therapeutics is set to expand its liver-targeted genetic disease franchise for the treatment of phenylketonuria (PKU).  Beam’s lead programme, BEAM-304, leverages the company’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to directly and durably correct mutations in the phenylalanine… Read More

#News

Neuronal inclusions in Huntington’s disease
#Genetic diseases #Harness Therapeutics #Huntington's disease #Neuroscience

Harness Therapeutics nominates drug candidate for Huntington’s

Harness Therapeutics has announced the nomination of HRN001 as its lead drug candidate for Huntington’s disease (HD).  The company has also formed a clinical advisory board to support the programme’s advancement towards clinical evaluation.  Despite significant advances in understanding HD disease biology, there are currently… Read More

#News

The European Medicines Agency in Amsterdam
#CHMP #European Commission #European Medicines Agency #Genetic diseases #Rare diseases #UCB

Kygevvi recommended in the EU for thymidine kinase 2 deficiency

UCB’s Kygevvi (doxecitine and doxribtimine) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation under exceptional circumstances.  The recommendation is for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d)… Read More

#News #Regulatory

Eye
#Advanced Therapies #FDA #Gene editing #Gene therapy #GenEditBio #Genetic diseases #Ophthalmology #Phase I trial

GenEditBio gets green light for in vivo genome-editing programme

The US Food and Drug Administration (FDA) has cleared GenEditBio to initiate Phase I/II CLARITY trial activities for its lead in vivo genome-editing programme GEB-101 for TGFBI corneal dystrophy.  The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients… Read More

#News #Regulatory #Trending News

Gene therapy
#Gene editing #Gene therapy #Genetic diseases #Huntington's disease #uniQure

Trial shows slowing of Huntington’s progression for the first time

A global clinical trial for a new Huntington’s disease gene therapy has posted positive results, including 75% less progression of the disease.  AMT-130 is the first gene therapy to be tested in people with Huntington’s. This is also the first time a drug trial has reported continuing,… Read More

#News #Trending News

#Cancer biology #Genetic diseases #Regenerative Medicine #Stem cells #Trogenix

Harnessing heterogeneity to treat cancer patients

Cancer is no longer seen as a simple disease of unchecked cell growth, but as a complex, adaptive ecosystem shaped by genetic mutations, immune evasion, and transcriptional plasticity that allow tumours to survive and evolve. Steve Pollard, CSO & Founder of Trogenix and Professor of Stem Cell and Cancer Biology,… Read More

#Cancer Research #Exclusive Content

DNA sequencing
#Genetic diseases #Genetics / genomes #Rare diseases #SynaptixBio #UK #UK government

UK genetic screening plan welcomed by biotech

The UK Government has announced that every newborn baby in England will have their genetic code mapped to test for a wide range of conditions, part of a plan that will also see £650m invested in DNA research by 2030.  The Department for Health and Social Care… Read More

#News

#Gene mutation #Gene therapy #Genetic diseases #Genetics / genomics

New DDW Highlights podcast: 16 June 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week’s round-up highlights the vital role of genetics in drug discovery, including new data… Read More

#News

#Gene mutation #Gene therapy #Genetic diseases #Genetics / genomics

This week in drug discovery (9-13 June) 

News round-up for 9-13 June by DDW Senior Digital Content Editor Diana Spencer. This week’s round-up highlights the vital role of genetics in drug discovery, including new data for an Alzheimer’s gene therapy, the discovery of a genetic target for rejuvenation therapies, and a 13-year follow up on… Read More

#News

Cell and gene therapy
#AAV #Financing #Gene therapy #Genetic diseases #Ophthalmology #SpliceBio

SpliceBio secures $135m to advance gene therapy candidates

SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures.  There was also participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.  The funding… Read More

#Business & Investment #News

#Genetic diseases #Huntington's disease #Neurodegenerative disorders #Neuroscience

Tipping point in Huntington’s disease research

Jan Thirkettle, CEO of Harness Therapeutics, looks at the emerging opportunities for drug discovery and development for Huntington's disease. Huntington's disease (HD) represents one of medicine's most significant unmet needs, affecting approximately 10 in 100,000 people, with over 200,000 people at risk of inheriting the disease in the US alone. Read More

#Exclusive Content

#Gene mutation #Genetic diseases #MHRA #Mitochondria #Rare disease #UCB

TK2d drug gets UK Promising Innovative Medicine designation

Dox – comprising of doxecitine and doxribtimine – to treat thymidine kinase 2 deficiency (TK2d) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA).  TK2d is caused by a genetic mutation in the TK2 gene. This mutation leads to… Read More

#News #Regulatory

#Gene therapy #Genetic diseases #Ophthalmology #Retinitis pigmentosa

Gene therapies for inherited retinal disorders

Christopher Doyle, PhD, Senior Director of IBC Services at WCG provides an overview of common approaches, emerging trends, and future prospects of gene therapies for inherited retinal disorders. Inherited retinal disorders (IRDs) are a group of genetically diverse conditions that lead to significant vision impairment and often culminate in complete… Read More

#Exclusive Content